Overview

KRDI in Transplant-Eligible MM

Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This research study is testing the efficacy of an experimental drug combination for people with newly diagnosed multiple myeloma that are eligible for a stem cell transplant. The names of the study drugs involved in this study are: - Carfilzomib - Isatuximab - Lenalidomide - Dexamethasone
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Amgen
Sanofi
Treatments:
Dexamethasone
Lenalidomide